Online supplement

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection

Yan Dan¹, MSc.; Xiao-Yan Liu¹, MSc.; Ya-nan Zhu², MSc.; Li Huang², MSc.; Bi-tang Dan¹, MSC.; Guo-jun Zhang³, PhD; Yong-hua Gao³, PhD

¹Department of Neurology, Hubei NO.3 People's Hospital of Jianghan University, Wuhan, Hubei, China

²Department of Internal Emergency Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

³Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Corresponding author: Dr Yong-hua Gao, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Email: gaoyonghuahust@163.com

Take home message: Risk factors for prolonged viral shedding included older age and lack of Lopinavir/Ritonavir treatment. Earlier administration of Lopinavir/Ritonavir treatment could shorten the duration of SARS-CoV-2 RNA shedding.

Table E1. Clinical features in patients with prolonged SARS-CoV-2 detection in Wuhan

Characteristic	Days to negativity		Darabasa
	≤23 d, n= 61	>23 d, n= 59	- P value
Age, Y	48 (33-60)	56 (42-65)	0.04
Male sex	30 (49.2)	24 (40.7)	0.35
Comorbidity			
Hypertension	19 (31.1)	13 (22.0)	0.26
Diabetes	3 (4.9)	7 (11.9)	0.20
Cardiac disease ^a	3 (4.9)	4 (6.8)	0.72
Stroke	1 (1.6)	2 (3.4)	0.62
COPD or asthma	2 (3.2)	0 (0)	
Malignancy	4 (6.6)	3 (5.1)	0.73
Disease severity			0.36
General	48 (78.7)	41 (69.5)	
Severe	13 (21.3)	17 (28.8)	
Critical	0 (0)	1 (1.7)	
Laboratory finding on admission			
White blood cell count, × 10 ⁹ cells/L			0.57
<4	16 (26.7)	11 (18.6)	
4-10	39 (65)	43 (72.9)	
>10	5 (8.3)	5 (8.5)	
Lymphocyte count, × 10 ⁹ lymphocytes/L			
<0.8	18 (62.1)	11 (37.9)	0.15
Platelet count, × 10 ⁹ platelets/L			
<100	5 (4.2)	2 (1.%)	0.44
Creatinine level, µmol/L			
>133	0 (0)	4 (3.4%)	
AST level, U/L			
>40	14 (11.8)	19 (16.0)	0.18
Treatment			
Corticosteroid therapy	28 (45.9)	26 (44.1)	0.78
Lopinavir/Ritonavir treatment	46 (75.4)	33 (55.9)	0.02
Antibiotics	52 (85.2)	50 (84.7)	0.77
High-flow nasal canula oxygen therapy	10 (16.4)	11 (18.6)	0.88
No-invasive mechanical ventilation	0 (0)	2 (3.4)	
Invasive mechanical ventilation	0 (0)	1 (1.7)	
Outcome			
viral shedding duration, d	18 (15-20.5)	32 (28-38)	<0.001
Hospital length of stay, d	20 (15-24)	22 (18-28)	0.02

Abbreviations: AST=aspartate aminotransferase; COPD=chronic obstructive pulmonary disease; d=day IQR=interquartile range.

Data presented as n (%) or median (IQR) unless otherwise noted.

^aincludes congestive heart disease and coronary atherosclerotic heart disease.